Skip to main content

Table 4 Efficacy evaluation

From: Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study

 

PK group (n = 109)

BSA group (n = 100)

CR

0 (0.00)

0 (0.00)

PR

40 (36.70)

34 (34.00)

SD

53 (48.26)

38 (38.00)

PD

16 (14.68)

28 (28.00)

  1. Data presented as No. (%) unless otherwise indicated. CR complete recession, PR partial recession, SD stable disease, PD progressed disease
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us